Chiltern Phase I unit gains supplementary accreditation
Chiltern’s early phase unit in Dundee, Scotland has achieved supplementary accreditation from the Medicines and Healthcare products Regulatory Agency (MHRA).
The accreditation is part of the MHRA’s voluntary two tiered scheme for Phase I units in the UK which assesses quality, safety and adherence to good laboratory practices (GLP).
Having met the criteria the Chiltern site, located in Ninewells Hospital and Medical School, is accredited to perform first in human (FIH) trials requiring clinical trial expert advisory group of the commission of human medicine (CTEAG) review.
“With the achievement of supplementary accreditation, Chiltern Early Phase is uniquely placed to offer a full range of early phase FIH / exploratory development studies including proof of concept / translational medicine studies”, said Glenn Kerkhof, CEO of Chiltern.
